-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29

Benzinga·05/13/2026 15:33:59
Listen to the news
JP Morgan analyst Brian Cheng maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and lowers the price target from $30 to $29.